retatrutide phase 2 results 2024 2025 The Effect of on Kidney Parameters in Participants With Type Diabetes Mellitus and/or Obesity Retatrutide FDA Approval 2025–2026: Phase

They serve as an adjunct tool to support continued appetite control and metabolic health in the long term

Studies show that GLP-1 receptor agonists, drugs that mimic GLP-1, have been shown to help people with type 2 diabetes (T2D) and obesity lose weight and control their blood sugar [2]

Higher protein intake (1.0-1.2 g/kg for older adults and 1.2-1.6 g/kg for those engaging in resistance training) may help preserve lean muscle mass

Retatrutide is being studied as a triple agonist, while tirzepatide is an approved dual agonist for certain indications

Scrambled control constructs and uninfected Neuro2a cells were used as controls

Compounded semaglutide is not FDA approved and may come with risks like dosing errors and contamination